© Oxford University Press 2006.
NEWS |
In Brief
R.J. Reynolds Will No Longer Market Flavored Cigarettes in the U.S.The R.J. Reynolds Tobacco Company has agreed to stop selling cigarettes flavored like candy, fruit, or alcohol, and it will accept tougher restrictions on marketing those products.
The decision was made when attorneys general from 40 states and one U.S. territory pressured the company into discontinuing sales of the cigarettes. The states were particularly interested in banning the sale of these cigarettes because of their appeal to children.
NCI Funds Part of Clinical Proteomic Technologies Initiative
The National Cancer Institute will fund $35.5 million of the $104 million, 5-year Clinical Proteomic Technologies Initiative for Cancer. The money will help bring together five teams to assess the protein and peptide measurement technologies relevant to clinical cancer research and practice.
Award recipients include the Broad Institute of MIT and Harvard in Boston; the University of California in San Francisco and Lawrence Berkeley National Laboratory in California; the Vanderbilt University School of Medicine in Nashville, Tenn.; Purdue University in West Lafayette, Ind.; and Memorial Sloan-Kettering Cancer Center in New York.
FDA Approves Bevacizumab for Lung Cancer
The U.S. Food and Drug Administration has approved the use of bevacizumab (Avastin) in combination with carboplatin and paclitaxel to treat advanced, metastatic, nonsquamous, non–small-cell lung cancer that cannot be surgically removed.
Previous trials have shown that median survival times increased to 12.3 months when bevacizumab was added to the regimen, compared with 10.3 months with carboplatin and paclitaxel alone. Bevacizumab has also been approved for use in metastatic colon or rectal cancer patients.
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||